← FDA DRUG APPROVALS

FDA ANDA · ANDA076685

SIMVASTATIN

Sponsor: WATSON LABS TEVA

APPLICATION
ANDA076685
TYPE
ANDA
ORIGINAL APPROVAL
2006-12-20
LATEST ACTION
2008-10-31
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

SIMVASTATINDiscontinued
SIMVASTATIN 10MG · TABLET · ORAL
SIMVASTATINDiscontinued
SIMVASTATIN 80MG · TABLET · ORAL
SIMVASTATINDiscontinued
SIMVASTATIN 20MG · TABLET · ORAL
SIMVASTATINDiscontinued
SIMVASTATIN 5MG · TABLET · ORAL
SIMVASTATINDiscontinued
SIMVASTATIN 40MG · TABLET · ORAL

Approval history

2008-10-31Labeling · Supplement 8AP
2008-06-18Labeling · Supplement 7AP
2007-08-14Labeling · Supplement 4AP
2006-12-20Original — Other Important Information from FDA ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →